CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+19.58%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$856M
AUM Growth
+$856M
(-3.9%)
Cap. Flow
+$82.2K
Cap. Flow
% of AUM
0.01%
Top 10 Holdings %
Top 10 Hldgs %
65.11%
Holding
33
New
7
Increased
9
Reduced
4
Closed
3
Top Buys
| 1 |
Rhythm Pharmaceuticals
RYTM
|
$47.6M |
| 2 |
Soleno Therapeutics
SLNO
|
$26.2M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
$14.9M |
| 4 |
Merus
MRUS
|
$10.1M |
| 5 |
VistaGen Therapeutics
VTGN
|
$8.25M |
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$56.1M |
| 2 |
Spyre Therapeutics
SYRE
|
$34.2M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$22.2M |
| 4 |
Arrowhead Research
ARWR
|
$21.8M |
| 5 |
Nuvalent
NUVL
|
$14.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RYZB
26
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $6.41M | 0.75% |
+288,911
| New | +$6.41M |
|
27
Apogee Therapeutics
APGE
$2.17B
| $5.33M | 0.62% |
+250,000
| New | +$5.33M |
|
28
Mersana Therapeutics
MRSN
$36.5M
| $2.85M | 0.33% |
+2,244,378
| New | +$2.85M |
|
|
29
Spyre Therapeutics
SYRE
$996M
| $1.42M | 0.17% |
116,324
-2,791,776
| -96% | -$34.2M |
|
|
DBVT
30
DBV Technologies
DBVT
$264M
| $126K | 0.01% |
92,687
| – | – |
|
|
31
Arrowhead Research
ARWR
$3.05B
| – | – |
-610,000
| Closed | -$21.8M |
|
32
KalVista Pharmaceuticals
KALV
$678M
| – | – |
-312,553
| Closed | -$2.81M |
|
|
CBAY
33
DELISTED
Cymabay Therapeutics
CBAY
| – | – |
-2,025,000
| Closed | -$22.2M |
|